CompletedPhase 4

Zinc Supplementation on Cellular Immunity in Thalassemia Major

Indonesia58 participantsStarted 2013-09-01

Plain-language summary

Randomized controlled trial was conducted in post-splenectomy patients aged \>12 years. Subjects are randomly assigned to two groups (zinc and placebo). 1.5 mg/kg/day (max 50 mg/day) of Zinc is administered.

Who can participate

Age range12 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Thalassemia major patients * Age \> 12 years * Agreed to participate and signed the informed consent * No other comorbidity beside thalassemia Exclusion Criteria: * HIV positive patients * Those in steroid medication

What they're measuring

Patient's T-lymphocyte count

Timeframe: 12 weeks

Trial details

NCT IDNCT03117192

SponsorFakultas Kedokteran Universitas Indonesia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2014-02-01

View on ClinicalTrials.gov More Thalassemia trials